US 11,690,879 B2
Dysosmobacter, a novel bacterial genus of the gastrointestinal microbiota and uses thereof
Patrice Cani, Brussels (BE); and Tiphaine Le Roy, Le Mans (FR)
Assigned to UNIVERSITÈ CATHOLIQUE DE LOUVAIN, Louvain la Neuve (BE)
Appl. No. 17/258,256
Filed by UNIVERSITÉ CATHOLIQUE DE LOUVAIN, Louvain la Neuve (BE)
PCT Filed Jul. 10, 2019, PCT No. PCT/EP2019/068539
§ 371(c)(1), (2) Date Jan. 6, 2021,
PCT Pub. No. WO2020/011856, PCT Pub. Date Jan. 16, 2020.
Claims priority of application No. 18305916 (EP), filed on Jul. 10, 2018.
Prior Publication US 2021/0338745 A1, Nov. 4, 2021
Int. Cl. A61K 35/74 (2015.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); C12N 1/20 (2006.01); A23L 33/135 (2016.01); A61K 8/99 (2017.01)
CPC A61K 35/74 (2013.01) [A61P 3/04 (2018.01); A61P 3/06 (2018.01); C12N 1/205 (2021.05); A23L 33/135 (2016.08); A61K 8/99 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A method for treating metabolic syndrome in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of at least one isolated bacterium belonging to the genus Dysosmobacter, wherein the nucleotide sequence of the 16S rRNA gene of said isolated bacterium has at least 98% identity with SEQ ID NO: 1.